Odalasvir

Odalasvir is an antiviral drug that was under development for the treatment of Hepatitis C. It is a NS5A inhibitor, a type of drug that interferes with the replication of the Hepatitis C virus.

Development

Odalasvir was developed by Achillion Pharmaceuticals, a biopharmaceutical company based in the United States. The drug was part of a combination therapy with other antiviral drugs, such as Sofosbuvir and Velpatasvir, for the treatment of Hepatitis C.

Clinical Trials

In clinical trials, Odalasvir showed promising results in reducing the levels of the Hepatitis C virus in the body. However, the development of the drug was discontinued in 2017 due to the emergence of more effective treatments for Hepatitis C.

Mechanism of Action

As a NS5A inhibitor, Odalasvir works by binding to the NS5A protein, a viral protein that plays a crucial role in the replication of the Hepatitis C virus. By inhibiting this protein, Odalasvir prevents the virus from replicating and spreading in the body.

Side Effects

Like other antiviral drugs, Odalasvir may cause side effects. These can include fatigue, headache, and nausea. However, the severity and frequency of these side effects can vary among individuals.

See Also

• Hepatitis C
• Antiviral drug
• NS5A inhibitor
• Achillion Pharmaceuticals